GlassScriptPhysician profile
Christopher J Mavroides
NPI 1265496251
$2,690.82
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $723 · 2021: $973 · 2022: $42.05.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $804.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $373.60 | 2019-2022 | |
| Lilly USA, LLC | $290.94 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $207.73 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $141.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Pfizer INC. | $59.47 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $59.21 | 2019 | |
| Horizon Therapeutics Plc | $31.59 | 2020-2021 | |
| Amgen INC. | $26.45 | 2021 | |
| Bausch Health US, LLC | $24.64 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $23.92 | 2021 | |
| Grt US Holding, INC. | $19.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.23 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16.29 | 2021 | |
| Amarin Pharma, INC. | $14.81 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.20 | 2021 | |
| Glaxosmithkline, LLC. | $12.66 | 2021 | |
| Abbvie INC. | $11.72 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mavroides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.